Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05394103. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901Administered Via Intravenous Infusion as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Selected Advanced Solid Tumors With Cohort Expansions at the Recommended Phase 2 Dose
Study identification
- NCT ID
- NCT05394103
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Qurient Co., Ltd.
- Industry
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Interventions
- Q901 Drug
- KEYTRUDA® (pembrolizumab) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 29, 2022
- Primary completion
- Dec 29, 2025
- Completion
- Aug 29, 2026
- Last update posted
- Aug 16, 2025
2022 – 2026
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | Recruiting |
| University of Southern California | Los Angeles | California | 90033 | Recruiting |
| Mayo Clinic | Jacksonville | Florida | 32224 | Recruiting |
| Northwestern University | Chicago | Illinois | 60611 | Recruiting |
| Mayo Clinic | Rochester | Minnesota | 55905 | Recruiting |
| Atlantic Health System Hospital | Morristown | New Jersey | 07960 | Recruiting |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05394103, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05394103 live on ClinicalTrials.gov.